October 14, 2021
OnKure Therapeutics Appoints Jennifer R. Diamond, M.D., as Chief Medical Officer
August 3, 2021
OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer
July 20, 2021
OnKure Builds its Discovery Team and Appoints Heads of Computational Drug Discovery and Pharmacology
OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancer. As a team of veterans with a track record of successful drug discovery and development, we are leveraging our proven structure-based drug design approach to create a robust pipeline of drug candidates that are designed to achieve optimal tolerability and efficacy. OnKure is currently developing its lead clinical candidate OKI-179, an oral Class 1 HDAC inhibitor, for the treatment of both hematological and solid tumors, as well as exploring other validated oncology targets and pathways. In the evolving landscape of precision oncology, our successful tumor-agnostic approach is key to discovering new treatments for cancer patients with unmet medical needs.